Study S001892

A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT00838903
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 1049
Start: 2009-02
Primary completion: 2012-01
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:albiglutide; DRUG:sitagliptin; DRUG:glimepiride; DRUG:metformin; BIOLOGICAL:placebo albiglutide; DRUG:placebo sitagliptin; DRUG:placebo glimepiride
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104 [Baseline and Week 104]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014141	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Home PD, Diabetes research and clinical practice	2017	Randomized trial	PMID 28683300 DOI	cites ClinicalTrials.gov:NCT00838903; registry reference DERIVED:28683300
R0035689	Albiglutide Superior to Sitagliptin and Glimepiride in T2DM E. Hitt, MD Conference Express	2013	Other trial	DOI	cites ClinicalTrials.gov:NCT00838903